canakinumab

FDA grants breakthrough therapy designations for canakinumab to treat periodic …
... since 2009 to treat cryopyrin-associated periodic syndrome, Muckle-Wells syndrome and familial cold autoinflammatory syndrome in patients 4 years and older. In 2013, it was approved to treat systemic juvenile idiopathic arthritis in patients 2 ... [...]
5
Like
Save